- Valirx
- 24 February 2025 15:11:32
Source: Sharecast
The AIM-traded company said it had synthesised, tested, and profiled the candidates against established therapeutics in a series of evaluations.
While the initial results showed promise, ValiRx said it had determined that the development programme remained at an early stage, adding that it had opted to return the project to Imperial College London for further development.
The collaboration agreement had been terminated, with no further financial commitment from ValiRx, and responsibility for maintaining the intellectual property reverting to the university.
“Working alongside the Imperial College London team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Imperial to hear further updates on these and other projects which could lead to future agreements,” said chief executive officer Mark Eccleston.
At 1437 GMT, shares in ValiRx were down 4.8% at 0.6p.
Reporting by Josh White for Sharecast.com.